Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Slides:



Advertisements
Similar presentations
Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Advertisements

ECSI case Fall 2014 Andrea M. Sheehan, MD Associate Professor of Pathology & Immunology Baylor College of Medicine.
An example of Flow Cytometric DNA Analysis as a diagnostic tool J. Chezar Western Galilee Hospital-Nahariay Israel.
李啟誠, 朱崧肇, 蔡喜修, 許淑敏, 謝馨慧 Michael R. Loken
Pei Lin, MD Department of Hematopathology UT M.D. Anderson Cancer Center, Houston, TX Monitoring of Minimal Residual Disease Principles and Applications.
Laser Flow Cytometry Forward Scatter indicates size Forward Scatter.
7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE CD49d and CD26 are independent prognostic markers for disease progression in patients.
Minimal Residual Disease(MRD) detections by Flow Cytometry in Acute Leukemia 혈액학파트 안 미 숙.
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
Society for Hematopathology/ European Association for Haematopathology 2013 Workshop Case 145 Nidhi Aggarwal, M.D.; Robert L. Redner, MD; Fiona E. Craig,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
May 29 - June 2, 2015 Leukemia Stem Cell Phenotypes Correlate With Cytogenetic Risk Factors and Outcomes CCO Independent Conference Highlights of the 2015.
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Monitoring of minimal residual disease in acute myeloid leukemia
Representative flow cytometry dot plots from a healthy individual
JONCKHEERE, Stijn 1; STEUR, Elise 1; BILLIET, Johan 1
Monitoring of minimal residual disease among multiple myeloma patients after autologous stem cell transplantation Fidan Akhundova, Larisa Mendeleeva, Irina.
Flow cytometric detection of minimal residual disease in B-lineage acute lymphoblastic leukemia by using “MRD lite” panel  Brig Tathagata Chatterjee,
Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;
Early T-Cell Precursor ALL in 5 Year Old Female
Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Reduced Frequency of Regulatory T Cells in Peripheral Blood Stem Cell Compared to Bone Marrow Transplantations  Céline Blache, Joe-Marc Chauvin, Aude.
How I treat hairy cell leukemia
Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.
Olga Sala Torra, Megan Othus, David W
IMMUNOPHENOTYPING LEUKEMIAS AND LYMPHOMAS
Immunologic defects in 22q11.2 deletion syndrome
Recruitment of myeloid and plasmacytoid dendritic cells in cervical mucosa during Chlamydia trachomatis infection  T. Agrawal, V. Vats, P.K. Wallace,
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia by Anna Rogers, Youngson.
Effect of High VEGF-C mRNA Expression on Achievement of Complete Remission in Adult Acute Myeloid Leukemia  Sung-Eun Lee, Ji Yoon Lee, A-Reum Han, Hee-Sun.
Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.
Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA  Giulia Biancon, Silvia Gimondi, Antonio Vendramin, Cristiana.
by David Grimwade, and Sylvie D. Freeman
A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia by S. Legras, U. Günthert, R. Stauder, F. Curt,
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Grövdal M et al. Blood 2008;112:Abstract 223.
Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis  Luis Escribano, MD, PhD, Andrés Garcı́a-Montero,
Flow cytometric analysis of putative progenitor cells.
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological.
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells by Fang Dong, Haitao.
Supplemental Digital Content 2 – Figure 1
Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma  Mark Korthals, Nina Sehnke, Ralf Kronenwett,
Floor Weerkamp, MSc, Edwin F. E. de Haas, BSc, Brigitta A. E
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation  Swati.
Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia  George L. Chen, Hong Liu,
Supplemental Digital Content 3 – Figure 2
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic.
Neoplastic disorder.
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-
Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country by Lorena Lobo de.
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.
(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.
Residual Cancer Lymphocytes in Patients With Chronic Lymphocytic Leukemia After Therapy Show Increased Expression of Surface Antigen CD52 Detected Using.
Minimal Residual Disease and Hematologic Malignancies
Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.
Early Recovery of CD4 T Cell Receptor Diversity after “Lymphoablative” Conditioning and Autologous CD34 Cell Transplantation  Jan Storek, Zhao Zhao, Yiping.
A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.
Outline of antibody groups used in panels for identification of AML-aberrant immunophenotypes (both for LAIP and “different-from-normal” approaches) and.
Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease  John M. Magenau,
Idarubicin-Intensified Hematopoietic Cell Transplantation Improves Relapse and Survival of High-Risk Acute Leukemia Patients with Minimal Residual Disease 
Presentation transcript:

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission (B). Cells from acute myeloid leukemia (AML) at diagnosis and follow-up BM samples are stained with a combination of monoclonal antibodies, which identifies a leukemia-associated phenotype (LAP). The gating strategy starts by defining the WBC compartment characterized by CD45 expression and SS Log. A, On these selected cells, the cell population with a primitive marker expression, in this case CD117, and low side scatter (SSC) is subsequently gated for detection of the cells with aberrant phenotypes. The patient experienced relapse within 6 months after achieving complete remission (CR). The aberrant phenotype was CD117+/CD15+ expression on the CD34+/CD117+ cells. The MRD percentages were 0.78%, 0.42%, and 0.64% after induction and consolidation I and consolidation II chemotherapy, respectively. The dot plot at the extreme right shows relapsed material with LAP expression similar to that at diagnosis. B, On these selected cells, the cell population with a primitive marker expression, in this case CD34, and low SSC is subsequently gated for detection of the cells with aberrant phenotypes. The patient was still in CR after 24 months. The LAP includes CD34+/CD7+ expression. The MRD percentages were 0.12%, 0.15%, 0.13%, and 0.09% after induction, consolidation I and consolidation II chemotherapy, and at follow-up, respectively. FITC, fluorescein isothiocyanate; PE, phycoerythrin; SS, side scatter. From: The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Am J Clin Pathol. 2015;131(1):16-26. doi:10.1309/AJCP5TSD3DZXFLCX Am J Clin Pathol | © American Society for Clinical Pathology

Figure 1 Algorithm used for identifying leukemia-associated phenotype (LAP) in patients with acute myeloid leukemia (AML) and for detection of minimal residual disease (MRD). Once LAP is identified, it will serve to establish a phenotype to trace residual leukemia after a complete remission is recognized morphologically. Adapted from Campana and Pui<sup>12</sup> and Campana and Coustan-Smith<sup>15</sup> and previous literature on MRD. ALL, acute lymphoblastic leukemia; BM, bone marrow; MoAbs, monoclonal antibodies; OS, overall survival; RFS, relapse-free survival; +, positive; −, negative. From: The Role of Multiparameter Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia Am J Clin Pathol. 2015;131(1):16-26. doi:10.1309/AJCP5TSD3DZXFLCX Am J Clin Pathol | © American Society for Clinical Pathology